Clinical Trial Update: Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 trial of combining radiation with PD-1 inhibition in metastatic or recurrent renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: WITHDRAWN